BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Shares of Biohaven Ltd. (BHVN) were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease. Currently, there are no FDA-approved therapy for the given indication. The study showed the efficacy of troriluzole on the mean change from baseline in the modified functional Scale for the Assessment and Rati ...